CanSino Biologics Launches Phase III Study for Menhycia Vaccine in Indonesia
China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study...
Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio
Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a...
Kelun-Biotech Reports Robust 91.6% Revenue Growth Amid Strategic Licensing Efforts
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) reported its 2023 financial results, revealing revenues of...
Guangdong Zhongsheng Reports Positive Phase I Results for Innovative Weight Loss Drug RAY1225
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based biopharmaceutical company, has announced promising top-line...
Zylox-Tonbridge Secures NMPA Approval for Advanced Flow Diverter Targeting Intracranial Aneurysms
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...
Novo Nordisk Expands Benzalkonium Chloride Distribution with Actylis Across Europe
Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with...
WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...
Jiangsu Hengrui’s Generic Version of Tepadina Approved for Transplantation Conditioning in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...
Sandoz Expands Antibiotics Production with New Austrian Factory
Sandoz (OTCMKTS: SDZNY), a Swiss pharmaceutical company, has announced the opening of a new antibiotics...
Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments
Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s...
EMA Panel Backs Novartis’s Fabhalta for PNH Treatment, Awaits EC Decision
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market
Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of...
Roche Invests EUR 90 Million in New Gene Therapy Center in Germany
Swiss pharmaceutical giant Roche (SWX: RO) has inaugurated a new gene therapy development center in...
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...
FibroGen’s Roxadustat Approved in Macau for Chronic Kidney Disease-Related Anemia
FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it...
China’s Commerce Minister Meets with Global Pharma Leaders to Discuss Innovation Cooperation
China’s Minister of Commerce, Wang Wentao, convened a high-level meeting with top executives from the...
Yifan Pharmaceutical’s F-627 Approved by European Commission for Marketing in EU
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that its subsidiary...
OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in...
Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...